# EDGAR Filing Document

**Accession Number:** 0002068530
**File Stem:** 0001104659-25-079821
**Filing Date:** 2025-8
**Character Count:** 24787
**Document Hash:** 867f7e5b93b385a81a48a15bb8d897ef
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-079821.hdr.sgml**: 20250818

**ACCESSION NUMBER**: 0001104659-25-079821

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250818

**DATE AS OF CHANGE**: 20250818

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** X4 Pharmaceuticals, Inc
- **CENTRAL INDEX KEY:** 0001501697
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 273181608
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90199
- **FILM NUMBER:** 251228236

**BUSINESS ADDRESS:**
- **STREET 1:** 61 NORTH BEACON STREET
- **STREET 2:** 4TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02134
- **BUSINESS PHONE:** 857-529-8300

**MAIL ADDRESS:**
- **STREET 1:** 61 NORTH BEACON STREET
- **STREET 2:** 4TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02134

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Arsanis, Inc.
- **DATE OF NAME CHANGE:** 20100920
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Coastlands Capital LP
- **CENTRAL INDEX KEY:** 0002068530

**ORGANIZATION NAME:**
- **EIN:** 333553930
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 601 CALIFORNIA STREET, SUITE 1210
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94108
- **BUSINESS PHONE:** (415) 249-1280

**MAIL ADDRESS:**
- **STREET 1:** 601 CALIFORNIA STREET, SUITE 1210
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94108

## Exhibit 99.1

EXHIBIT 99.1

AGREEMENT REGARDING JOINT FILING

OF STATEMENT ON SCHEDULE 13D OR 13G

The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Coastlands Capital LP, a Delaware limited partnership, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

Dated: August 18, 2025

---

| | | | |
|:---|:---|:---|:---|
| **COASTLANDS CAPITAL LP**<br>By: Coastlands Capital LLC,<br>General Partner | **COASTLANDS CAPITAL LP**<br>By: Coastlands Capital LLC,<br>General Partner | **COASTLANDS CAPITAL PARTNERS LP<br>**<br> By: Coastlands Capital GP LLC,<br>General Partner | **COASTLANDS CAPITAL PARTNERS LP<br>**<br> By: Coastlands Capital GP LLC,<br>General Partner |
| By: | /s/ *Mark Shamia* | By: | /s/ *Mark Shamia* |
| Mark Shamia | Mark Shamia | Mark Shamia | Mark Shamia |
| Chief Operating Officer | Chief Operating Officer | Chief Operating Officer | Chief Operating Officer |
| **COASTLANDS CAPITAL LLC** | **COASTLANDS CAPITAL LLC** | **COASTLANDS CAPITAL GP LLC** | **COASTLANDS CAPITAL GP LLC** |
| By: | /s/ *Mark Shamia* | By: | /s/ *Mark Shamia* |
| Mark Shamia | Mark Shamia | Mark Shamia | Mark Shamia |
| Chief Operating Officer | Chief Operating Officer | Chief Operating Officer | Chief Operating Officer |
|  |  | /s/ *Matthew D. Perry* | /s/ *Matthew D. Perry* |
|  |  | Matthew D. Perry | Matthew D. Perry |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**X4 Pharmaceuticals, Inc**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**98420X202**

*(CUSIP Number)*

**Mark Shamia**<br>Coastlands Capital LP<br>601 California Street, Suite 1210<br>San Francisco CA 94108<br>(415) 249-1282

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**08/11/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **98420X202** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Coastlands Capital LP** | Name of reporting person<br>**Coastlands Capital LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2479645.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2479645.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2479645.00** | Aggregate amount beneficially owned by each reporting person<br>**2479645.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.99%** | Percent of class represented by amount in Row (11)<br>**9.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

**Comment for Reporting Person:** Percentage calculated based on 11,408,357 shares of Common Stock outstanding on August 4, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025, plus 11,040,776 shares of Common Stock issued in a private placement transaction, which closed on August 13, 2025. The securities exclude shares of Common Stock issuable upon exercise of a pre-funded warrant in excess of the beneficial ownership limitation of 9.99%.

| **CUSIP No.** | **98420X202** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Coastlands Capital Partners LP** | Name of reporting person<br>**Coastlands Capital Partners LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2479645.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2479645.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2479645.00** | Aggregate amount beneficially owned by each reporting person<br>**2479645.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.99%** | Percent of class represented by amount in Row (11)<br>**9.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Percentage calculated based on 11,408,357 shares of Common Stock outstanding on August 4, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025, plus 11,040,776 shares of Common Stock issued in a private placement transaction, which closed on August 13, 2025. The securities exclude shares of Common Stock issuable upon exercise of a pre-funded warrant in excess of the beneficial ownership limitation of 9.99%.

| **CUSIP No.** | **98420X202** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Coastlands Capital GP LLC** | Name of reporting person<br>**Coastlands Capital GP LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2479645.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2479645.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2479645.00** | Aggregate amount beneficially owned by each reporting person<br>**2479645.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.99%** | Percent of class represented by amount in Row (11)<br>**9.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Percentage calculated based on 11,408,357 shares of Common Stock outstanding on August 4, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025, plus 11,040,776 shares of Common Stock issued in a private placement transaction, which closed on August 13, 2025. The securities exclude shares of Common Stock issuable upon exercise of a pre-funded warrant in excess of the beneficial ownership limitation of 9.99%.

| **CUSIP No.** | **98420X202** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Coastlands Capital LLC** | Name of reporting person<br>**Coastlands Capital LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2479645.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2479645.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2479645.00** | Aggregate amount beneficially owned by each reporting person<br>**2479645.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.99%** | Percent of class represented by amount in Row (11)<br>**9.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**HC** | Type of Reporting Person (See Instructions)<br>**HC** | |

---

**Comment for Reporting Person:** Percentage calculated based on 11,408,357 shares of Common Stock outstanding on August 4, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025, plus 11,040,776 shares of Common Stock issued in a private placement transaction, which closed on August 13, 2025. The securities exclude shares of Common Stock issuable upon exercise of a pre-funded warrant in excess of the beneficial ownership limitation of 9.99%.

| **CUSIP No.** | **98420X202** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Matthew D. Perry** | Name of reporting person<br>**Matthew D. Perry** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**2479645.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**2479645.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**2479645.00** | Aggregate amount beneficially owned by each reporting person<br>**2479645.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.99%** | Percent of class represented by amount in Row (11)<br>**9.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Percentage calculated based on 11,408,357 shares of Common Stock outstanding on August 4, 2025, as reported in the Form 10-Q filed by the Issuer for the quarter ended June 30, 2025, plus 11,040,776 shares of Common Stock issued in a private placement transaction, which closed on August 13, 2025. The securities exclude shares of Common Stock issuable upon exercise of a pre-funded warrant in excess of the beneficial ownership limitation of 9.99%.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
X4 Pharmaceuticals, Inc

**(c) Address of Issuer's Principal Executive Offices:**
61 North Beacon Street, 4th Floor, Boston, MA, 02134

**Item 4. Purpose of Transaction**

Concurrent with the August 2025 Financing, the Issuer's board of directors (the "Board") approved (i) the termination of each of the Chief Executive Officer and Chief Financial Officer of the Company and (ii) the appointment of an Executive Chairman, a new Chief Financial Officer and a new President of the Company.

Except as described in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D, although, the Reporting Persons, at any time and from time to time, may review, reconsider and change their position and/or change their purpose and/or develop such plans and may seek to influence management or the board of directors of the Company with respect to the business and affairs of the Company and may from time to time consider pursuing or proposing such matters with advisors, the Issuer or other persons.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information set forth in Items 2, 3 and 6 and on the cover pages of this Schedule 13D is incorporated by reference in its entirety into this Item 5.

As of the date hereof, Coastlands directly holds 107,500 shares of Common Stock and a pre-funded warrant exercisable for up to 7,047,216 shares of Common Stock.

As a result of the Beneficial Ownership Blocker (as defined below), the Reporting Persons are precluded from exercising the pre-funded warrant into shares of Common Stock to the extent that the Reporting Persons would, after such exercise, collectively beneficially own in excess of 9.99% of the outstanding Common Stock of the Issuer. Accordingly, pursuant to Rule 13d-3 of the Act and the relationships described in Item 2 of this Schedule 13D, the Reporting Persons may be deemed to collectively beneficially own 9.99% of the outstanding Common Stock of the Issuer, representing 2,479,645 shares of Common Stock as of the date hereof.

The calculation of the beneficial ownership of the Reporting Persons is based on (i) 11,408,357 shares of Common Stock issued and outstanding as of August 4, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Securities and Exchange Commission on August 8, 2025; (ii) 11,040,776 shares of Common Stock issued by the Issuer in the August 2025 Financing; and (iii) 2,372,145 shares of Common Stock issuable upon the exercise of the pre-funded warrant held by the Reporting Persons, which reflects the Beneficial Ownership Blocker.

**(b)**
See Item 5(a) hereof.

**(c)**
See Item 3 of this Schedule 13D.

On August 12, 2025, the Reporting Persons purchased 107,500 shares of Common Stock in the open market at a price per share of $1.7074, for an aggregate purchase price of $183,545.50.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Pre-Funded Warrants

Exercisability. The pre-funded warrant held by the Reporting Persons is exercisable at any time after its original issuance.

Exercise Blocker. Exercise of each pre-funded warrant is prohibited if, as a result of such exercise, the holder, together with its affiliates and other persons whose beneficial ownership would be aggregated with the holder's for purposes of Section 13(d) of the Act, would beneficially own more than 9.99% of the total number of shares of Common Stock then issued and outstanding immediately after giving effect to the exercise (the "Beneficial Ownership Blocker").

Exercise Price. The Reporting Persons hold pre-funded warrants exercisable for up to 7,047,216 shares of Common Stock with an exercise price of $0.001 per share. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations or reclassifications affecting the Common Stock.

Fundamental Transaction. If a Fundamental Transaction (as defined in the pre-funded warrant) occurs while a pre-funded warrant is outstanding, then upon any subsequent exercise of the pre-funded warrant, the holder thereof has the right to receive the same amount and kind of securities, cash or property as such holder would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of shares of Common Stock then issuable upon exercise in full of the pre-funded warrant (without regard to any limitations on exercise).

Rights as a Stockholder. Except as otherwise provided in the pre-funded warrant or by virtue of the holder's ownership of Common Stock, the holder of a pre-funded warrant does not have the rights or privileges of a holder of Common Stock, including any voting rights, until the holder exercises the pre-funded warrant.

References to and the description of the pre-funded warrant set forth in this Item 6 do not purport to be complete and are qualified in their entirety by reference to the form of pre-funded warrant, which is attached hereto as Exhibit 99.3 and incorporated by reference herein.

Registration Rights Agreement

The Reporting Persons have entered into a resale registration rights agreement with the Issuer in connection with the August 2025 Financing pursuant to which the Issuer agreed to file a registration statement covering the resale, by the Reporting Persons, of certain shares of Common Stock held by the Reporting Persons and to use commercially reasonable efforts to cause such registration statement to remain effective until such time as all such shares of Common Stock have been sold or no longer qualify as registrable securities.

References to and the description of the registration rights agreement set forth in this Item 6 do not purport to be complete and are qualified in their entirety by reference to the registration rights agreement, which is attached hereto as Exhibit 99.4 and incorporated by reference herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Coastlands Capital LP

**Signature:** /s/ Mark Shamia

**Name/Title:** Chief Operating Officer of the General Partner, Coastlands Capital LLC

**Date:** 08/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Coastlands Capital Partners LP

**Signature:** /s/ Mark Shamia

**Name/Title:** Chief Operating Officer of the General Partner, Coastlands Capital GP LLC

**Date:** 08/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Coastlands Capital GP LLC

**Signature:** /s/ Mark Shamia

**Name/Title:** Chief Operating Officer

**Date:** 08/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Coastlands Capital LLC

**Signature:** /s/ Mark Shamia

**Name/Title:** Chief Operating Officer

**Date:** 08/18/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Matthew D. Perry

**Signature:** /s/ Matthew D. Perry

**Name/Title:** Reporting person

**Date:** 08/18/2025